---
figid: PMC9181681__jcm-11-03101-g005
pmcid: PMC9181681
image_filename: jcm-11-03101-g005.jpg
figure_link: /pmc/articles/PMC9181681/figure/jcm-11-03101-f005/
number: Figure 5
figure_title: ''
caption: 'Results of gene ontology (GO) enrichment analysis of NRDC in GSE102238.
  (A) Biological process categories of enriched terms. (B) Kyoto Encyclopedia of Genes
  and Genomes (KEGG) pathway analysis of NRDC, printed by p-values and gene counts.
  (C) The expression of NRDC in different cancer types. Bar plots profiling gene expression
  between tumor samples (red) and paired normal samples (blue). (BLCA: bladder urothelial
  carcinoma; BRCA: breast invasive carcinoma; CHOL: cholangiocarcinoma, COAD: colon
  adenocarcinoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; HNSC:
  head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal
  clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LIHC: liver hepatocellular
  carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; PRAD:
  prostate adenocarcinoma; READ: rectum adenocarcinoma; STAD: stomach adenocarcinoma;
  THCA: thyroid carcinoma; UCEC: uterine corpus endometrial carcinoma; **: p < 0.01;
  ***: p < 0.001).'
article_title: Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
citation: Yongfeng Xu, et al. J Clin Med. 2022 Jun;11(11):3101.
year: '2022'

doi: 10.3390/jcm11113101
journal_title: Journal of Clinical Medicine
journal_nlm_ta: J Clin Med
publisher_name: MDPI

keywords:
- nardilysin
- serum biomarker
- bioinformatics tools
- pancreatic ductal adenocarcinoma
- carbohydrate antigen 19-9

---
